Komori
Eiken Chemical (4549) · InitiativeAdvanced

Three priority business areas under EIKEN ROAD MAP 2030

First written in FY2022. 7 of 9 entries say "Restated". Latest entry: FY2026.

9entries
5years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022 – 2026-05-122022: 320222023: 220232024: 120242025: 120252026: 22026
Same theme, other companies
Growth strategy focused on cancer, infectious diseases and healthcare as priority business areasA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In the field of “cancer,” we will focus on areas more directly linked to treatment. In the field of “infectious diseases,” we will focus on establishing simpler testing technologies. In the field of “healthcare,” we will expand products and services that can support telehealth checkups and at-home testing.」

    While continuing to pursue the three priority business areas, the company specified the focus areas as cancer treatment, simple testing for infectious diseases, and telehealth checkups and at-home testing for healthcare.
  2. 2026-05-12RestatedManagement plan

    「No change in the business areas and strategic direction targeted for FY2030」

    The company stated that it will maintain the FY2030 business areas and strategic direction centred on cancer, infectious diseases and healthcare.
  3. FY2026-H1RestatedAnnual report

    「While developing key initiatives centered on the three priority business areas of “contributing to cancer prevention and treatment,” “contributing to the eradication of infectious diseases and infection control,” and “providing products and services beneficial to healthcare,” our group will pursue fundamental transformation to strengthen its earnings base.」

    The company continues to develop initiatives centered on the three priority business areas under EIKEN ROAD MAP 2030.
  4. FY2024-Q3RestatedAnnual report

    「There were no material changes to the management policies, management strategies or other matters established by our Group during the cumulative third-quarter period.」

    The company states that there have been no material changes to its management policies or management strategies, including the three priority business areas under EIKEN ROAD MAP 2030.
  5. FY2024-Q1RestatedAnnual report

    「Under these business conditions, the Group is implementing priority measures centered on three focus business areas in line with the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030”: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」

    The company continues to use a framework for developing key initiatives centered on the three priority business areas under EIKEN ROAD MAP 2030.
  6. FY2023-Q3RestatedAnnual report

    「Based on the medium-term management plan formulated under the management vision EIKEN ROAD MAP 2030, our group is developing key initiatives centered on the three priority business areas of “contributing to cancer prevention and treatment,” “contributing to the eradication of infectious diseases and infection control,” and “providing products and services beneficial to healthcare,” while working across the group to achieve sustainable growth and steadily improve profitability.」

    The company continues to develop key initiatives centered on the three priority business areas of cancer, infectious diseases and healthcare.
  7. FY2023-Q2RestatedAnnual report

    「Under these business conditions, the Group is implementing priority measures centered on three focus business areas in line with the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030”: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」

    The company continues to pursue a policy of developing key initiatives centered on the three priority business areas under EIKEN ROAD MAP 2030.
  8. FY2023-Q1RestatedAnnual report

    「The company is developing key initiatives centered on three priority business areas: “contributing to cancer prevention and treatment,” “contributing to the eradication of infectious diseases and infection control,” and “providing products and services beneficial to healthcare,”」

    The company continues to develop initiatives centered on the three priority business areas of cancer, infectious diseases and healthcare under EIKEN ROAD MAP 2030.
  9. FY2022First statedAnnual report

    「Under EIKEN ROAD MAP 2030, while positioning the current business domains as core businesses, the company has established three priority business areas: “contributing to cancer prevention and treatment,” “contributing to the eradication of infectious diseases and infection control,” and “providing products and services beneficial to healthcare.”」

    The new roadmap toward 2030 identified cancer, infectious diseases and healthcare as priority business areas for the first time.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Eiken Chemical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Management plan of 2026-05-12: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Three priority business areas under EIKEN ROAD MAP 2030 | EIKEN CHEMICAL CO.,LTD. (4549) | Komori